Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrarectal botulinum toxin for fecal incontinence: rectal motility mechanisms study
2022-003817-12Phase 3Active
- Sponsor
- Rouen University Hospital
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in fecal incontinence (FI), sponsored by Rouen University Hospital. Primary endpoint: Time to onset of high amplitude propagative contractions after Dulcolax instillation. Started Jan 2023; status: active.
02
Drugs
botulinum toxin type A
03
Conditions
fecal incontinence (FI)
Beyond the preview
Go deeper on 2022-003817-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003817-12.